Ariad to defend patent infringement claims by Amgen, others

By Lisa Kerner

Erie, Pa., April 24 - Ariad Pharmaceuticals, Inc. said Amgen, Inc. and affiliated entities have filed suit in the U.S. District Court for the District of Delaware regarding U.S. Patent No. 6,410,516 covering methods of treating disease by regulating NF-(kappa) B cell-signaling activity.

According to a news release, the action seeks a declaratory judgment that each of the claims contained in the patent are invalid and that Amgen and its affiliated entities have not infringed any claims of the '516 patent based on activities related to the products, Enbrel and Kineret.

Four of the claims of the '516 patent are the subject of an ongoing trial in the U.S. District Court for the District of Massachusetts in a patent infringement lawsuit brought by Ariad, Massachusetts Institute of Technology, Harvard University and the Whitehead Institute for Biomedical Research, against Eli Lilly and Co. alleging infringement by Lilly of the '516 patent claims through sales of Lilly's osteoporosis drug Evista and Lilly's septic shock drug Xigris.

Ariad said it believes there is no basis for the declaratory relief sought by Amgen and will contest Amgen's claims as without merit.

Located in Cambridge, Mass., Ariad develops medicines to treat cancer by regulating cell signaling with small molecules.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.